We thank Wang and Zhong for raising the important considerations on limitation or withdrawal of therapy in the MOSAICS II studies [
1]. Although limitation or withdrawal of therapy was not part of the exclusion criteria for MOSACIS II, data on subsequent limitation of therapy or withdrawal of therapy during ICU stay was collected but not previously published [
2,
3]. Amongst the 4826 patients included in the MOSACIS II secondary analysis on qSOFA prognostic value, only 5.9% (283/4826) had withdrawal of life-sustaining treatments and 5.9% (287/4826) had withholding of life-sustaining treatments [
3]. Even amongst those who died within 28 days, only 11.2% (142/1271) and 10.8% (137/1271) had withdrawal or withholding of life-sustaining treatments prior to death. Overall, low rates of limitation of therapy suggest it may not have significantly biased the conclusions drawn about prognostic value of qSOFA in sepsis. …